Advertisement
Home Tags Prescription Drugs

Tag: Prescription Drugs

Drug Makers Raise Prices on 500 Prescription Drugs

U.S. Drug Prices 256 Percent Higher Than in 32 OECD Countries

0

U.S. prices higher than those in comparison countries for brand-name originator drugs, but lower for unbranded generics

Dexamethasone Not Favored for Chronic Subdural Hematoma

Metformin Use for T2DM May Reduce COVID-19 Mortality

0

Odds of contracting COVID-19, COVID-19-related mortality higher for individuals with diabetes

Metformin Recalled Due to Contamination With Carcinogen

Adverse Drug Reactions Linked to Hydroxychloroquine Up in 2020

0

ADRs associated with hydroxychloroquine, chloroquine more than doubled in 2020 versus 2018 and 2019

Sixty-Day Outcomes Examined for Hospitalized COVID-19 Patients

COVID-19 Outcomes No Worse for Patients on Immunosuppressive Meds

0

Findings for ventilator use, length of stay, in-hospital mortality similar for those with, without chronic use of immunosuppressant agents

No Evidence Found to Support Discontinuing ACEIs, ARBs in COVID-19

0

Mean number of days alive and out of hospital not significantly different for those discontinuing, continuing meds

La vacuna de Pfizer contra la COVID parece promisoria

Bamlanivimab + Etesevimab Reduces SARS-CoV-2 Viral Load

0

No significant reduction seen in viral load at day 11 with bamlanivimab monotherapy in mild-to-moderate COVID-19

FDA Approves First Once-a-Month HIV Therapy

FDA Approves First Monthly Injectable Regimen for HIV

0

Trials show virologic suppression in comparable numbers of patients receiving monthly injection with Cabenuva, daily current antiretroviral regimen

ASH: Daratumumab + Pomalidomide

Antibody Drug May Protect Nursing Home Residents, Staff From COVID-19

0

Preliminary results of the study conducted by drug maker Eli Lilly have not been peer-reviewed or published

WHO: Remdesivir Not Advised for Hospitalized COVID-19 Patients

Tocilizumab Does Not Improve Outcomes in Severe COVID-19

0

Tocilizumab plus standard care no better for improving clinical outcomes at 15 days and may increase mortality

Denosumab Studied for Prosthesis-Related Osteolysis

0

Fewer osteoclasts seen at osteolysis membrane-bone interface with denosumab versus placebo in patients undergoing revision hip arthroplasty